GlassScriptPhysician profile
Mohamed Altattan
NPI 1477932093
$11,692.03
in general payments reported to CMS, 2019-2025
25 companies · $6,218 in 2025
The $6,218 reported for 2025 was more than what 87% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $335 · 2022: $413 · 2023: $308 · 2024: $4,418 · 2025: $6,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,190 · Consulting Fee: $2,430 · Education: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,189.65 |
| Consulting Fee | $2,430.00 |
| Education | $324.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,704.32 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $1,697.12 | 2023-2025 | Krystexxa, Tavneos, Enbrel |
| Ucb, INC. | $1,438.32 | 2024-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $1,232.85 | 2021-2025 | Rinvoq, Humira |
| Novartis Pharmaceuticals Corporation | $578.22 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $540.76 | 2024-2025 | Orencia |
| Genzyme Corporation | $340.45 | 2024-2025 | |
| Pfizer INC. | $300.22 | 2021-2025 | |
| Fresenius Kabi USA, LLC | $230.83 | 2024-2025 | Idacio |
| Lilly USA, LLC | $227.55 | 2023-2024 | Taltz |
| Ani Pharmaceuticals, INC. | $224.19 | 2024-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $221.68 | 2024-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $189.77 | 2023-2025 | Benlysta |
| Invivyd INC | $121.46 | 2025 | Pemgarda |
| Mallinckrodt Hospital Products INC. | $116.53 | 2022-2024 | Acthar |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $114.26 | 2024-2025 | |
| Smith+Nephew, INC. | $102.64 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $85.93 | 2024 | Arcalyst |
| Genentech USA, INC. | $54.78 | 2024-2025 | Actemra |
| Aurinia Pharma U.S., INC. | $46.83 | 2024-2025 | Lupkynis |
| Organon LLC | $32.45 | 2025 | Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.40 | 2023 | Cyltezo |
| Alexion Pharmaceuticals, INC. | $24.83 | 2025 | Strensiq |
| Tonix Medicines, INC. | $24.60 | 2025 | Tonmya |
| Horizon Therapeutics Plc | $16.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Altattan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.